Candidature YC de Nomic Bio

Winter 2020Active

Nomic Bio a été sélectionné par Y Combinator dans le cadre du batch Winter 2020 en tant qu'entreprise Healthcare. Ci-dessous : ce que fait l'entreprise, qui l'a fondée, et sa candidature à YC, reconstruite question par question dans le vrai formulaire YC.

Batch YC: Winter 2020
Secteur d'activité: HealthcareDiagnostics
Taille de l'équipe: 24
Statut: Active
Lancé: 2020

Fondateurs

Milad DagherFounder
Jeff MunzarFounder

Ce que fait Nomic Bio

Nomic is doing for protein profiling, what Illumina did for DNA sequencing. Our core technology, the nELISA, is a next-gen immunoassay platform that transforms the ELISA into a high-throughput, high-content, and high-versatility tool. Today we developed the nELISA for high-throughput drug discovery scientists, enabling them profile 100s of proteins at 10x higher throughput and 10x lower cost compared to existing solutions. We're offering the nELISA through early access programs to HTS groups in top pharmas as well as pioneering biotechs in the space. Our goal is to create a ubiquitous technology that consolidates the broad range of legacy immunoassay toolkits that scientists use today with a single platform that can carry the science end-to-end, from discovery all the way to the clinic. We're a team of engineers, biologists, and highly-skilled lab operators that are looking to grow quickly to keep up with customer demand but also to continue developing our core technology, scale our multiplexing/throughput, and build our software stack. We're hiring on a number of positions including engineering, software, biology, and ops. Come talk to us!

Candidature YC de Nomic Bio, reconstruite

Candidature Y Combinator

Nomic Bio, promotion Winter 2020. Les vraies questions de candidature, répondues à partir de données publiques.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Nomic Bio

Describe what your company does in 50 characters or less.

Protein profiling like Illumina did for DNA

What is your company going to make? Please describe your product and what it does or will do.

We built the nELISA, a next-generation immunoassay platform that lets drug discovery scientists profile hundreds of proteins simultaneously with 10x higher throughput and 10x lower cost than current solutions. Unlike legacy ELISA kits, our platform scales high-content protein measurement for early discovery through to clinical use, consolidating multiple assay types into one versatile tool.

Where do you live now, and where would the company be based after YC?

We live in Montreal, QC, Canada, and plan to keep the company based here after YC.

Explain your decision regarding location.

Montreal has the local expertise in biochemistry, engineering, and nanotech that our platform requires. It also offers a strong, low-cost talent pool compared to typical US hubs and aligns with the founders' personal ties and initial lab setup.

21 réponses supplémentaires dans la candidature complète

se trouvent dans la version complète. Créez un compte gratuit pour l'ouvrir dans YC Insights, à côté de tous les autres batches YC.

Voir la candidature complète

Questions fréquemment posées

Est-ce la vraie candidature YC de Nomic Bio ?

Non. Y Combinator garde les candidatures soumises privées. Ceci est une reconstruction : les vraies questions du formulaire YC, répondues à partir des données publiques de Nomic Bio (notes de lancement, parcours des fondateurs, description du produit). Cela montre comment une entreprise comme Nomic Bio se présenterait à YC, pas le texte qu'ils ont soumis.

À quel batch YC Nomic Bio appartenait-il ?

Nomic Bio faisait partie du batch Winter 2020 de Y Combinator.

Qui a fondé Nomic Bio ?

Nomic Bio a été fondé par Milad Dagher, Jeff Munzar.

Que fait Nomic Bio ?

Nomic is doing for proteins what Illumina has done for DNA

Comment lire la candidature complète reconstruite ?

Créez un compte Round Funded gratuit. La version complète de la candidature de Nomic Bio en 26 réponses, et de chaque autre promotion YC, se trouve dans YC Insights.